Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- Yasuhisa Shiozaki Tapped as New Health Minister
September 3, 2014
- MHLW Will Discuss Freezing NHI Prices of Essential Drugs if Industry Requests It: MHLW Official Nakai
September 3, 2014
- MOF Official Unami Urges Full-Scale NHI Price Revision upon Next Sales Tax Hike
September 2, 2014
- METI to Request 20% Increase in Budget for Promotion of Science and Technology: FY2015 Budget Request
September 2, 2014
- MHLW to Reinforce Follow-Up Surveys on HPV Vaccine Recipients
September 1, 2014
- MHLW Prods Univ. of Tokyo to Set Up Third-Party Panel over J-ADNI
September 1, 2014
- MHLW Notifies Prefectures of RMP Submissions for Generics
August 29, 2014
- New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
August 29, 2014
- MHLW Notifies Health Professionals of Revised Package Insert for Simeprevir
August 28, 2014
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
- MHLW Calls for Maintenance of Current R&D Tax Credit Limit
August 27, 2014
- PFSB’s FY2015 Budget Request Seeks Funding to Increase PMDA Staff by 13 to Strengthen Its Consultation System
August 27, 2014
- MHLW’s FY2015 Budget Request at Record 31.67 Trillion Yen, Includes 74.8 Billion Yen to Promote Commercialization of Innovative New Drugs
August 27, 2014
- PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
- MHLW to Promote Joint Drug Development by Pharmas, Academia
August 26, 2014
- PAFSC’s First Committee to Discuss Lixiana’s Additional Use on Sept. 4
August 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 11 - August 22
August 25, 2014
- PMDA Reviewing Lyrica for Risk of Fulminant Hepatitis, Hepatic Dysfunction
August 25, 2014
- Eisai Sues FDA over Shortened Exclusivity Time for Belviq, Fycompa
August 22, 2014
- MHLW Plans to Build Clinical Trial/Clinical Research Network with Centralized Disease-Based Patient Registry: FY2015 Preliminary Budget Request
August 22, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…